01 — At a Glance
The Oncology Bet That’s Finally Showing Returns
- 52-Week High / Low₹502 / ₹260
- Q3 FY26 Revenue₹410 Cr
- Q3 FY26 EBITDA₹115 Cr
- Q3 EPS (Quarterly)₹2.28
- 9M FY26 Revenue₹1,110 Cr
- Book Value₹125
- Price to Book2.49x
- Debt / Equity0.24x
- Dividend Yield0.16%
- YoY Revenue Growth+28% (Q3)
Auditor’s Opening Note: Shilpa Medicare just fired on all cylinders. Q3 FY26 delivered ₹410 crore revenue (highest ever), 28% EBITDA margin, and formulations grew 50% YoY to ₹177 crore. The 9-month PAT already sits at ₹146 crore — nearly double of full-year FY25. Management’s concall message: capex cycle largely over; now it’s execution, scaling, and ROCE recovery. Stock is at 34.7x P/E. Premium justified? Let’s find out.
02 — Introduction
The Oncology Company That’s Learning to Walk (And Run)
Meet Shilpa Medicare — a ₹6,138 crore market cap company that manufactures oncology APIs, complex formulations, and biologics. For most investors, that sounds like “complicated.” For the company, it means they’ve spent the last five years building pipes, GMP facilities, R&D labs, and capability centres across five cities. The total capex+R&D bill? ₹12 billion.
Now, in Q3 FY26, three things happened simultaneously:
One, formulations exploded 50% YoY. Two, EBITDA hit record levels at ₹115 crore with a 28% margin. Three, management said on the concall (Feb 2026): “whatever heavy lifting was required on the investment side, we have largely completed.” Translation: The burn is over. The bloom is on.
But here’s the catch — you’re paying ₹315 per share for a stock at 34.7x P/E. That’s not oil-company multiples (Castrol trades at 19x). That’s a growth stock multiple. So either Shilpa is about to justify it with explosive scalability, or it’s a very expensive laboratory experiment. The concall gives us clues. The Q3 numbers give us data. Let’s separate the science fiction from the actual science.
Concall Highlight (Feb 2026): Management on capex: “Investment cycle largely done; pivot to execution, scaling and ROCE.” Translation from corporate-speak: We built the spaceship. Now we’re launching it. Buckle up or bail out.
03 — Business Model: WTF Do They Even Make?
Oncology APIs, Complex Formulations, and Biologics That Cost ₹12 Billion to Build
Shilpa Medicare has three main segments, each with wildly different margins, growth rates, and regulatory complexity.
Segment 1: APIs (Active Pharmaceutical Ingredients) — The Foundation. They manufacture 30+ oncology APIs (basically, the working ingredient in cancer drugs). Customers include global generic companies, big pharma, and contract manufacturers. This business generated ₹243 crore in Q3 (including captive consumption), growing 11% YoY. Margins? Decent. Growth? Slow. Stock volatility? High (because raw material costs and customer inventory levels whipsaw revenue quarter to quarter). Regulatory risk? Yes — they have a USFDA import alert on their Jadcherla facility (small stuff, but worth monitoring).
Segment 2: Formulations — The Growth Engine. They manufacture injectable oncology drugs, oral solids, and now fancy stuff like oral dissolving films and transdermal patches. Revenue in Q3: ₹177 crore, up 50% YoY. Licensing income (milestone-based payments from partners) makes up 14% of revenue. This is where the excitement lives. Complex products, high margins, limited competition.
Segment 3: Biologics (SBPL) — The Moonshot. Biosimilars (copycat biologics), novel biologics, and synthetic albumin. Currently 6% of consolidated revenue. Expected to be a major growth driver in FY27+. Capex has been ~₹3 billion over 5 years just for this segment. It’s not profitable yet. But management swears it’ll scale.
APIs (Captive)₹243 CrQ3 FY26
Formulations₹177 CrQ3 FY26 (+50% YoY)
Others~₹10 CrCMO, Licensing
Total Revenue₹410 CrHighest ever
Backward Integration Play: Shilpa increased backward integration from 15% (FY24) to 25% (FY25). What does that mean? They’re making their own APIs and feeding them into their formulations plants instead of buying from third parties. Higher margins. Less external revenue visibility. But better profitability on the blended portfolio.
💬 Quick thought experiment: If formulations grow 50% YoY for two more years, where’s the ceiling? Drop your thoughts — or just say “finally a pharma story that isn’t VLS Logistics 2.0.”
04 — Financials Overview: Q3 FY26
The Numbers That Made Investors Stop Complaining
